Pembrolizumab (Keytruda) works by blocking the interaction between PD-1 receptors on T-cells and PD-L1 on tumor cells, thereby unleashing the patient’s immune system to recognize and attack malignant cells (Figure 8) [116]. Here, CD274 is linked to neoplasm.